Kleefstra syndrome: 2026 so far

A real-world medication signal was paired with mechanism work.

In the months covered, an international cohort report described improved adaptive functioning (everyday daily-life skills) in some people with Kleefstra syndrome who received olanzapine, without a reported comparison group. In that cohort, 10 of 16 people were reported to have sustained improvement and 4 had temporary improvement, which keeps this in the category of an observational signal rather than proof of benefit. The same work linked the clinical observations to lab findings of neuronal hyperactivity (overactive nerve-cell signaling) tied to higher S100B, and reported that olanzapine (and lowering S100B) reduced this overactivity in models. This can help families discuss whether day-to-day functioning changes are worth tracking during olanzapine use, while recognizing the report does not show who will benefit or how much change is due to the drug.

Research covered in: June 2026

Care became more structured, while evidence gaps were highlighted.

A new international guideline for Kleefstra syndrome type 1 (EHMT1-related) brought existing knowledge into one roadmap covering diagnosis, surveillance, and day-to-day supports across multiple body systems. It emphasized coordinated, multi-specialty care and included practical follow-up areas families often face (for example sleep, constipation/feeding, speech and language, hearing/vision checks, and seizure/EEG evaluation when needed), plus transition planning and discussion of reported regression episodes in adolescence/adulthood. The guideline also stated the limitations of the evidence: much of the literature was described as limited and often case-report based, so many recommendations relied on expert consensus. This gives families and clinicians a clearer shared structure for what may be monitored and supported, while being upfront about which parts are not yet strongly evidence-backed.

Research covered in: January 2026

Reports added concrete reference ranges and flagged under-detected issues.

In the months covered, a larger retrospective review (a look back at existing records) of 100 molecularly confirmed cases reported concrete reference points for early milestones (with wide variation), including a median independent walking age of about 2 years and first words at 24 months. Separately, a caregiver survey across rare genetic syndromes (including Kleefstra syndrome) reported sleep problems were more common than in typically developing children and that greater sleep difficulty was linked with higher anxiety/depressed mood and with more severe epilepsy and physical health problems, though this was not Kleefstra-only. Also, a single case report described QT prolongation (a heart electrical timing change) appearing during exercise testing despite a normal resting ECG, suggesting some rhythm differences may be missed by resting tests alone. Together, these reports add context for tracking development and sleep, and they raise a cautious question about exercise-related rhythm testing, without showing how predictive or how common these patterns are in Kleefstra syndrome.

Research covered in: February 2026, June 2026

More causes and clearer variant interpretation reduced some uncertainty.

In the months covered, several reports aimed to make the diagnosis clearer when someone looks clinically Kleefstra-like. Small studies expanded the list of genetic causes beyond EHMT1, including three new KS2 (KMT2C) cases and reports strengthening EHMT2 as a cause of a Kleefstra-like neurodevelopmental condition, including overlap in DNA methylation episignatures (a DNA 'chemical-tag' pattern used for diagnosis) with KLEFS1 in a de novo EHMT2 series. For EHMT1 itself, a lab-and-computer framework grouped many missense variants (single-letter DNA changes that swap one amino acid) as more likely tolerated versus damaging and reduced (but did not eliminate) uncertainty, with 18% still remaining uncertain in that analysis. This growing set of tools and gene explanations may help interpret unclear results and explain Kleefstra-like features, even though it still does not reliably predict day-to-day outcomes.

Research covered in: January 2026, March 2026, May 2026, July 2026, September 2026

Infrastructure advanced toward quicker testing of tailored approaches.

A research pipeline connected clinical sampling to making induced pluripotent stem cells (reprogrammed cells that can become many cell types) and neurons at scale, along with a proof of principle for rapidly creating oligonucleotide therapeutics (short, designed genetic molecules meant to change gene activity) for Kleefstra syndrome. This work included a cohort with biobanked stem cells and described the process as a way to speed translation from genetic findings to neuron-based testing. However, it did not report treatment outcomes in people or address patient safety/benefit. For families, this mainly signals faster research workflows rather than a change in clinical care right now.

Research covered in: September 2026